After Canary submitted an ETF application related to Injective, INJ re-entered the market spotlight. The article states that this application strengthened market expectations for Injective to gain institutional attention and prompted traders to reassess the token’s future price movement.
Incorporate staking rewards into the product design.
Based on the application, the proposed fund code is INJS. The product will hold INJ while allocating a portion of its holdings for staking to earn network rewards. This means investors will not only gain exposure to the token’s price movement but may also benefit from staking rewards.
The document also states that the product will be custodied by BitGo and will use a cash subscription and redemption mechanism. To address Injective's unbonding period, a liquidity reserve has been established to support investor redemptions.
Market focus shifts to institutional narratives.
Beyond Bitcoin and Ethereum, traditional institutions have recently begun to take greater interest in additional digital assets. The article suggests that Injective differentiates itself from certain other Layer 1 projects by covering DeFi, derivatives infrastructure, tokenized assets, and cross-chain applications.
If the relevant ETF progresses smoothly, Injective’s visibility among traditional investors could further increase. For some capital, the regulated product structure combined with staking yield design is the primary reason this application has attracted attention.
INJ price focuses on $4 and $5.20
From a price performance perspective, INJ is still in a recovery phase following its earlier pullback. The article notes that support has formed multiple times near $4, with recent buying activity concentrated in this area, making it a key defensive level for now.
The immediate short-term resistance is near $5.20. If this level is breached, the price may further test the $6 area. Looking further ahead, $7 to $7.50 is considered the next major resistance zone.
If INJ continues to hold above $4, the market may further monitor whether it has the potential to move toward $5.50 and $6.00. This ETF application has brought Injective back onto investors' radar; the focus now shifts to whether institutional interest can translate into sustained buying pressure.